XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.3

Revenues (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2023 and 2022:

			Three months ended September 30,												Nine months ended September 30,
			2023						2022						2023						2022
Products:
Kristalose			$	3,887,476					$	3,903,305					$	12,313,321					$	11,418,673
Sancuso			1,933,222						3,960,652						5,736,981						10,756,411
Vibativ			2,789,579						1,909,750						6,785,592						6,008,005
Caldolor			1,155,509						921,811						3,316,866						3,075,355
Acetadote			120,052						99,792						440,071						337,685
Vaprisol			—						(436)						39,866						(252,059)
Omeclamox-Pak			23,288						35,600						28,832						31,925
RediTrex			(122,556)						85,809						(254,108)						238,712
Other revenue			299,356						496,789						1,792,020						1,272,562
Total net revenues			$	10,085,926					$	11,413,072					$	30,199,441					$	32,887,269

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration